Company Overview and News

0
Bajaj Finserv Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJFINSV 532978

0
Bajaj Finserv Limited - Updates

2018-07-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJFINSV 532978

1
Closing Bell: Banks, RIL lift Sensex 267 pts; Nifty ends above 10,750 despite weak Asia

2018-07-04 moneycontrol
Global Update: Asian markets ended in the red with China's Shanghai Composite losing a percent after recording gains in the previous session. Trade tensions remained in the spotlight ahead of a looming tariff deadline, reports CNBC.
BAJAJ-AUTO KOHINOOR MUTHOOTFIN BHRYY 500325 UBL RELIANCE 532978 532977 533398 SRTRANSFIN 532478 511218 532783 532187 532121 506690 534816 RIGD SRRQY HDFCBANK BJJQY INFRATEL RLNIY 500034 UNICHEMLAB INDUSINDBK UBHOLDINGS 539126 UNBWY MEP 512559 BAJAJFINSV BAJFINANCE HDB 500180 DENABANK 507458 DAAWAT

0
Market Live: Nifty at day#39;s high, Sensex up over 250 pts; Bajaj Auto, Bharti Infratel top gainers

2018-07-04 moneycontrol
Buzzing: Unichem Laboratories share price rallied more than 5 percent intraday after the company received final ANDA approval for its Montelukast Chewable tablets, 4 mg and 5 mg from the United States Food and Drug Administration to market in the US.
BAJAJ-AUTO KOHINOOR BHRYY 500325 UBL RELIANCE 532978 532977 SRTRANSFIN 532478 511218 532783 532121 506690 534816 RIGD SRRQY BJJQY INFRATEL RLNIY 500034 UNICHEMLAB UBHOLDINGS UNBWY 512559 506022 BAJAJFINSV BAJFINANCE PRAKASH DENABANK 507458 DAAWAT

4
Market Live: Sensex up 150 pts despite global weakness; HDFC twins, RIL lead

2018-07-04 moneycontrol
Europe Update: European stocks were slightly lower Wednesday morning, amid elevated tensions between the US and China over looming trade tariffs and investment restrictions.
BAJAJ-AUTO KOHINOOR 500325 533271 UBL RELIANCE ASHOKA 532978 532977 532712 SRTRANSFIN 532478 511218 532783 500470 532121 RCOM RIGD SRRQY BJJQY 500570 TATAMOTORS 509488 RLNIY 500034 GRAPHITE UBHOLDINGS 532967 UNBWY KIRIINDUS BHEL 512559 506022 BAJAJFINSV BAJFINANCE TTST TATASTEEL TATLY PRAKASH BRHTY 500103 DENABANK 507458 DAAWAT TTM

4
Market Live: Rangebound trade continues at Dalal Street; Shriram Transport tumbles

2018-07-04 moneycontrol
Ducon Infratechnologies at upper circuit; Shares of Ducon Infratechnologies were locked at 20 percent upper circuit at Rs 22.80 following new orders for its US subsidiary.
BAJAJ-AUTO 500325 533271 UBL RELIANCE ASHOKA 532978 532977 532712 SRTRANSFIN 532478 511218 500470 532121 RCOM RIGD SRRQY BJJQY 500570 TATAMOTORS 509488 RLNIY 500034 GRAPHITE UBHOLDINGS 532967 UNBWY KIRIINDUS BHEL 506022 BAJAJFINSV BAJFINANCE TTST TATASTEEL TATLY PRAKASH BRHTY 500103 DENABANK 507458 TTM

4
Market Live: Sensex, Nifty, Midcap indices open flat; Asia weak amid trade tensions

2018-07-04 moneycontrol
VST Tillers corrects: Share price of VST Tillers Tractors slipped as much as 3 percent in morning on the back of poor sales number reported by the company for the quarter and month ended June 2018.
BAJAJ-AUTO 500325 533271 RELIANCE ASHOKA 532978 532977 532712 500470 RCOM RIGD BJJQY 500570 TATAMOTORS 509488 RLNIY 500034 GRAPHITE 532967 KIRIINDUS BHEL BAJAJFINSV BAJFINANCE TTST TATASTEEL TATLY BRHTY 500103 TTM

0
Bajaj Finserv Limited - Updates

2018-07-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJFINSV 532978

5
Closing Bell: Sensex rises 114 pts, Nifty ends tad below 10,700; pharma, auto, IT outshine

2018-07-03 moneycontrol
Global Update: Asian stocks closed mixed as investors remained cautious ahead of a July 6 deadline when the US is set to impose tariffs on $34 billion worth of goods from China. Beijing is then expected to respond with charges of its own on US goods, reports CNBC.
500325 UBL TTQQY 532478 TATACHEM CADILAHC 532321 BJJQY 500570 500770 RLNIY 513010 AXB MRZUY 532500 AXBA BAJAJFINSV BAJFINANCE 532670 TATASTEEL TATLY MARUTI 500180 KOTAKBANK 507458 523204 SSWL 513262 533271 RELIANCE IDBI 532737 ASHOKA 532978 RENUKA 532215 ABAN 500470 AXISBANK RIGD TATASPONGE HDFCBANK NIHARINF TATAMOTORS 500034 500116 KMBKY TATAMETALI IBN UBHOLDINGS 513434 532967 KIRIINDUS UNBWY CDLYY AXBKY ICICIBANK TTST EMKAY HDB 532174 531083 500247 TTM

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...